Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 3.225
-0.030 (-0.92%)
Mar 31, 2025, 2:35 PM CET
Oryzon Genomics Revenue
In the year 2024, Oryzon Genomics had annual revenue of 7.36M EUR, down -48.15%.
Revenue
7.36M
Revenue Growth
-48.15%
P/S Ratio
28.47
Revenue / Employee
159.97K
Employees
46
Market Cap
210.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.36M | -6.83M | -48.15% |
| Dec 31, 2023 | 14.19M | -1.51M | -9.60% |
| Dec 31, 2022 | 15.70M | 5.08M | 47.88% |
| Dec 31, 2021 | 10.62M | 1.09M | 11.49% |
| Dec 31, 2020 | 9.52M | -756.51K | -7.36% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.21B |
| Laboratorios Farmaceuticos Rovi | 763.75M |
| Almirall | 990.63M |
| Pharma Mar | 174.86M |
| Faes Farma | 510.04M |
| Clínica Baviera | 265.72M |
| Atrys Health | 211.11M |
| Laboratorio Reig Jofre | 338.90M |
Oryzon Genomics News
- 4 weeks ago - Oryzon Genomics S.A. GAAP EPS of -$0.02 - Seeking Alpha
- 2 months ago - ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting - Benzinga